Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

17.21USD
11:11am EDT
Change (% chg)

$-0.36 (-2.05%)
Prev Close
$17.57
Open
$17.52
Day's High
$17.66
Day's Low
$17.21
Volume
110,234
Avg. Vol
426,796
52-wk High
$19.94
52-wk Low
$13.00

Chart for

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $2,655.78
Shares Outstanding(Mil.): 150.90
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -0.79 -- --
ROI: -20.19 -0.71 13.13
ROE: -305.46 -2.76 14.96

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

* EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​ Source text for Eikon: Further company coverage:

Feb 15 2018

BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce

* SAYS ‍COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT​

Jan 30 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

Jan 16 2018

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017

Jan 08 2018

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

Dec 04 2017

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

Nov 28 2017

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage:

Nov 02 2017

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

Nov 02 2017

Earnings vs. Estimates